Literature DB >> 29442546

VEGF therapy for the kidney: emerging strategies.

Erika Guise1, Alejandro R Chade1,2,3.   

Abstract

Renovascular disease (RVD), which is prevalent in the elderly, significantly increases cardiovascular risk and can progressively deteriorate renal function. The loss of renal function in patients with RVD is associated with a progressive dysfunction, damage, and loss of renal microvessels, which can be combined with decreased renal bioavailability of vascular endothelial growth factor (VEGF) and a defective vascular repair and proliferation. This association has been the impetus for recent efforts that have focused on developing methods to stop the progression of renal injury by protecting the renal microvasculature. This mini-review focuses on recent studies supporting potential applications of VEGF therapy for the kidney and discusses underlying mechanisms of renoprotection.

Entities:  

Keywords:  angiogenesis; drug delivery; intervention; microcirculation; renovascular disease

Mesh:

Substances:

Year:  2018        PMID: 29442546      PMCID: PMC6230739          DOI: 10.1152/ajprenal.00617.2017

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  52 in total

Review 1.  Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus.

Authors:  Bernard I Levy; Ernesto L Schiffrin; Jean-Jacques Mourad; Denis Agostini; Eric Vicaut; Michel E Safar; Harry A J Struijker-Boudier
Journal:  Circulation       Date:  2008-08-26       Impact factor: 29.690

2.  Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease.

Authors:  T D Henry; K Rocha-Singh; J M Isner; D J Kereiakes; F J Giordano; M Simons; D W Losordo; R C Hendel; R O Bonow; S M Eppler; T F Zioncheck; E B Holmgren; E R McCluskey
Journal:  Am Heart J       Date:  2001-11       Impact factor: 4.749

3.  Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension.

Authors:  Jeffrey S Gilbert; Joseph Verzwyvelt; Drew Colson; Marietta Arany; S Ananth Karumanchi; Joey P Granger
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

4.  High-risk clinical presentations in atherosclerotic renovascular disease: prognosis and response to renal artery revascularization.

Authors:  James Ritchie; Darren Green; Constantina Chrysochou; Nicholas Chalmers; Robert N Foley; Philip A Kalra
Journal:  Am J Kidney Dis       Date:  2013-09-26       Impact factor: 8.860

5.  Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.

Authors:  H P Gerber; A McMurtrey; J Kowalski; M Yan; B A Keyt; V Dixit; N Ferrara
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

Review 6.  Ischemic nephropathy: where are we now?

Authors:  Stephen C Textor
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

7.  Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress.

Authors:  Xiang-Yang Zhu; Alejandro R Chade; Martin Rodriguez-Porcel; Michael D Bentley; Erik L Ritman; Amir Lerman; Lilach O Lerman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-08-12       Impact factor: 8.311

8.  Renal Therapeutic Angiogenesis Using a Bioengineered Polymer-Stabilized Vascular Endothelial Growth Factor Construct.

Authors:  Alejandro R Chade; Nathan A Tullos; Taylor W Harvey; Fakhri Mahdi; Gene L Bidwell
Journal:  J Am Soc Nephrol       Date:  2015-11-05       Impact factor: 10.121

9.  Chronic hypoxia attenuates VEGF signaling and angiogenic responses by downregulation of KDR in human endothelial cells.

Authors:  Barbara Olszewska-Pazdrak; Travis W Hein; Paulina Olszewska; Darrell H Carney
Journal:  Am J Physiol Cell Physiol       Date:  2009-02-25       Impact factor: 4.249

10.  Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis.

Authors:  J D Pearlman; M G Hibberd; M L Chuang; K Harada; J J Lopez; S R Gladstone; M Friedman; F W Sellke; M Simons
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

View more
  5 in total

1.  Microvascular remodeling and altered angiogenic signaling in human kidneys distal to occlusive atherosclerotic renal artery stenosis.

Authors:  Nattawat Klomjit; Xiang-Yang Zhu; Alfonso Eirin; Aditya S Pawar; Sabena M Conley; Amrutesh S Puranik; Christopher M Ferguson; Seo Rin Kim; Hui Tang; Kyra L Jordan; Ishran M Saadiq; Amir Lerman; Joseph P Grande; Stephen C Textor; Lilach O Lerman
Journal:  Nephrol Dial Transplant       Date:  2022-09-22       Impact factor: 7.186

Review 2.  The renal microcirculation in chronic kidney disease: novel diagnostic methods and therapeutic perspectives.

Authors:  Shulin Li; Fei Wang; Dong Sun
Journal:  Cell Biosci       Date:  2021-05-17       Impact factor: 7.133

Review 3.  Inflammation and Oxidative Damage in Ischaemic Renal Disease.

Authors:  Áine M de Bhailís; Constantina Chrysochou; Philip A Kalra
Journal:  Antioxidants (Basel)       Date:  2021-05-25

Review 4.  Microvascular disease in chronic kidney disease: the base of the iceberg in cardiovascular comorbidity.

Authors:  Uwe Querfeld; Robert H Mak; Axel Radlach Pries
Journal:  Clin Sci (Lond)       Date:  2020-06-26       Impact factor: 6.124

5.  Large Vessel Disease Modifies the Relationship Between Kidney Injury and Cerebral Small Vessel Disease.

Authors:  Dong-Hui Ao; Fei-Fei Zhai; Fei Han; Li-Xin Zhou; Jun Ni; Ming Yao; Ding-Ding Zhang; Ming-Li Li; Xiao-Hong Fan; Zheng-Yu Jin; Li-Ying Cui; Shu-Yang Zhang; Yi-Cheng Zhu
Journal:  Front Neurol       Date:  2018-06-26       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.